CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $61.99, moving +1.66% from the previous trading session. This move topped the S&P 500’s daily gain of 1.23%. Meanwhile, the Dow experienced an increase of 1.06%, and the technology-dominated Nasdaq saw an increase of 1.7%.
Prior to today’s trade, shares of the company had gained 0.63% over the past month. This trailed the gain of the Medical sector of 3.16% and the gain of S&P 500 of 0.94% at that time.
CRISPR Therapeutics AG’s upcoming earnings release will be of great interest to investors. The company is forecast to report EPS of -$0.22, marking an 84.4% increase compared to the same quarter last year. At the same time, our latest consensus estimate expects the revenue to be $144.28 million, showing a 1442670% escalation compared to the fourth year.
It’s also important for investors to be aware of some recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions usually reflect the latest short-term business trends, which can change frequently. Therefore, upward revisions in ratings express analysts’ positivity toward the company’s business operations and its ability to generate profits.
Empirical research indicates that these revisions in valuations have a direct correlation with short-term stock price performance. To take advantage of this, we created the Zacks Rank, a unique model that incorporates these rating changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, out-of-control track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate witnessed a 7.3% decline. Currently, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical – Biomedical and Genetic industry is part of the Medical sector. Currently, this industry has a Zacks Industry Rank of 89, placing it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our particular industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, at Zacks.com.
Only $1 to See All Zacks Buys and Sells
We’re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all of our options for the total sum of just $1. No obligation to spend another cent.
Thousands took advantage of this opportunity. Thousands didn’t – they thought there must be a catch. Yes, we do have a reason. We want you to familiarize yourself with our portfolio services such as Surprising Trader, Stocks Under $10, Technology Innovators,and more. They have already closed 162 positions with double and triple digit gains in 2023 alone.
View Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.